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Abstract The data from 11,040 patients of the European
Cardiovascular Magnetic Resonance (EuroCMR) registry
pilot phase offer the first documentation of the clinical use
of CMR in a routine setting. The pilot data show that CMR is
frequently performed in clinical practice, is a safe procedure
with excellent image quality, and has a strong impact on
patient management. In the future, the EuroCMR registry will
help to set international benchmarks on appropriate indica-
tions, quality, and safety of CMR. In addition, outcome and
cost effectiveness will be addressed on an international level
in order to develop optimized imaging-guided clinical path-
ways and to avoid unnecessary or even harmful testing.
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Introduction
Cardiovascular imaging is a source of innovation and
controversy for the health care community. Rapid techno-
logical advances and new clinical applications in cardio-
vascular imaging technology have led to explosive growth
in cardiovascular imaging. However, there are increasing
concerns that the rapid dissemination of cardiovascular
imaging may cause harm [1, 2], and may be a prime
example of a costly technology that is enthusiastically
embraced without appropriate supporting scientific evi-
dence. In general, the “value” of cardiac imaging technol-
ogies in terms of improved health outcomes or reduced
cardiovascular events remains subjective with limited
evidence [3, 4]. Furthermore, especially in economically
challenging times, considerations like length of stay and
cost effectiveness become increasingly important.
In the past decade, cardiovascular magnetic resonance
(CMR) has been added to the armamentarium of noninva-
sive imaging tools. One of the major advantages of CMR is
the unique concept of pulse sequences, which can be
arranged in a variety of protocols, allowing a greater range
of clinical questions to be addressed within a single
examination than any other noninvasive imaging technique.
Depending on the protocol, CMR can be used for
assessment of cardiac morphology, function, ischemia,
viability, valves, and great vessels, as well as for myocardial
tissue characterization [5–10].
Although the data available from controlled single and
multicenter trials are very promising, safety, clinical utility,
impact on patient management, and prognostic value of
CMR used in daily clinical practice remain unknown. The
EuroCMR registry sought to answer these questions and to
elucidate the current clinical role of CMR in an interna-
tional multicenter and multivendor real-life scenario.
Results of the German Pilot Phase
With 11,040 patients from 20 German centers enrolled
between April 2007 and January 2009, the pilot phase
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clinical practice of CMR [11].
The most frequent CMR indications were work-up of
myocarditis and cardiomyopathies (31.9%), risk stratification
in suspected coronary artery disease (CAD)/ischemia testing
(30.8%), and viability imaging (14.8%).
In contrast with most previous clinical trials, patients
with complicating conditions such as dyspnea at rest,
obesity, or atrial fibrillation were not excluded from the
registry. Nevertheless, image quality was rated as “good or
diagnostic” in more than 98% of studies.
CMR had significant impact on patient management in
nearly two thirds of all subjects by direct therapeutic
consequences or revealing a completely new diagnosis
(16.4%) not suspected before. Notably, in a subgroup of
23% of EuroCMR registry patients with no other imaging
test performed prior to CMR, impact on patient manage-
ment remained equally high without the need for additional
imaging procedures post-CMR in the majority of patients
(80%) in this subgroup.
In patients (n=3,351) who underwent stress CMR for work-
up of suspected CAD or evaluation of ischemia in known
CAD, invasive angiography could be avoided in 45% of cases.
Finally, CMR was a safe procedure in the routine clinical
setting with severe complications occurring in 0.05% of
patients only, exclusively related to stress testing. Not one
patient died during or due to CMR.
Lessons Learned from the Pilot Phase
First of all and given the high and increasing number of
patients enrolled in the registry, the basic strength of the
registry is to constantly redefine and monitor current
CMR utilization patterns in a routine clinical setting. At
present, work-up of heart failure, CAD, and viability
imaging are the major indications for referral to CMR
imaging in Germany. However, the registry data also
suggest that new indications may grow over time, such
as work-up of valvular heart disease prior to percutane-
ous aortic valve replacement [12], perfusion stress
imaging at 3.0 T [13], or interventional CMR related to
electrophysiology studies [14]. These data reflecting the
distribution of indications in real-life cardiology are
essential to monitor the adherence of CMR practitioners
to current guidelines and appropriateness criteria for
imaging, which is an important part of quality control.
Thus, the list of indications derived from the pilot phase
datasets of the EuroCMR registry suggests that current
clinical CMR practice is in good agreement with the
appropriateness criteria [15]. In the future, however, a
change in indications may inversely stimulate changes in
guidelines or promote new prospective clinical trials
(Fig. 1).
The second lesson to be learned from the EuroCMR
registry is that of procedural quality and safety. The data
from the pilot phase clearly indicate that routine CMR
performed by cardiologists or radiologists is a safe
procedure with very few major complications that are
exclusively related to stress testing. Furthermore, the
German pilot data demonstrate that image quality is
diagnostic in most routine patients without the limitations
of strict exclusion criteria as commonly encountered in
previous controlled trials.
Launching the second phase of the EuroCMR registry on
a European level and later the third phase on an
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Fig. 1 The role and interaction
of the European Cardiovascular
Magnetic Resonance
(EuroCMR) registry to
promote optimized patient man-
agement. CAD—coronary artery
disease; CHF—congestive heart
failure; HCM—hypertrophic
cardiomyopathy; SCD—sudden
cardiac death. (From Bruder
et al. [11]; with permission.)
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setting international benchmarks for safety, quality, and cost
of CMR imaging. Participating centers in return will be
able to constantly challenge the safety and quality of their
local setups with these international benchmarks derived
from the registry.
The diagnostic performance of CMR has been highlighted
by many landmark studies, such as on stress CMR for the
detection of CAD [9, 16, 17￿￿], viability imaging [6], or
tissue characterization in patients with ischemic or non-
ischemic cardiomyopathies [8, 18, 19]. The second step to
developing effective imaging strategies would be to relate
CMR parameters to clinical outcome and to demonstrate their
independent prognostic capability in comparison with the
established clinical prognosticators in single or multicenter/
multivendor trials. As a result of these scientific efforts,
preliminary knowledge has been generated about the prog-
nostic impact of stress CMR in patients with known or
suspected CAD [20], the extent of late gadolinium enhance-
ment (LGE) as a prognosticator of recovery of function in
patients with ischemic heart disease [7], or the presence and
extent of LGE in patients with dilated cardiomyopathies
[21]. For taking the third step toward an optimal imaging
strategy, data are needed on the impact of CMR results on
patient management. For the first time, the EuroCMR
registry pilot offers this crucial piece of information to
CMR imagers around the world. This generates the pilot
data’s third lesson, that the clinical effectiveness (accuracy
and outcome) of CMR can be translated in a strong impact
on patient management. CMR, in the real world, alters
patient management by changes in medical treatment,
diagnostic procedures, or timing of hospital discharge/
admission. Remarkably, in a substantial number of studies
CMR offered a completely unexpected and new diagnosis
for further clinical decision making, which is in good
agreement with the personal experience of many CMR
investigators. However, this information has not been
available on a scientific basis so far.
Developing optimized clinical pathways for cardiac
imaging modalities like CMR inevitably includes the
reduction of unnecessary testing, including layer testing
and repeat testing. In order to pursue this objective, the
EuroCMR registry part one (quality/safety/utility) will also
monitor procedures done before and after CMR imaging.
On this topic, the pilot data offer new and important
information as well:
1) CMR reduces the need for additional post-test imaging:
CMR avoids unnecessary invasive angiography in
nearly half of patients undergoing stress CMR. Addi-
tional noninvasive imaging involving ionizing radiation
(ie, single photon emission CT [SPECT] imaging and
CT coronary angiography) is performed only in a
minority of patients following CMR. CT and nuclear
imaging are the main sources of radiation exposure of
the general population in the United States [22]. And
although dose reduction algorithms are becoming
increasingly available with CT coronary angiography,
there is still a broad range of radiation exposure in a
real-life international, multicenter, and multivendor
setting [23￿￿].
2) In a subgroup of patients or with specific indications,
CMR may serve as the only imaging procedure needed
to satisfy all questions of the referrer, which was the
case in about 25% of patients in the German pilot
phase.
In contrast with clinical trials on new medical or invasive
treatment options, patient-focused outcome research in
cardiac imaging, answering the ultimate question “does
the patient live better and/or longer by using CMR”
compared to standard imaging is more challenging for the
advanced imaging modalities. However, limiting radiation
exposure and invasiveness, a lesson learned from the
EuroCMR pilot data, may be regarded as a surrogate
parameter for an improvement in patient care and quality of
life.
Only after proper investigation of quality, safety, and
impact of CMR imaging, trials investigating comparative
outcome and cost efficiency can be addressed. An excellent
example of a comparative outcome and cost effectiveness
trial is the ISCHEMIA trial, which compares stress
echocardiography, CMR, and SPECT followed by invasive
coronary angiography or optimal medical treatment in
patients with suspected CAD. The authors speculate that,
given the high effectiveness and clinical utility of CMR,
stress CMR without the risk of radiation exposure may turn
out to be the cornerstone of a patient-targeted imaging
strategy in suspected CAD, replacing SPECT nuclear
imaging in the near future.
Conclusions
With growing availability of diagnostic procedures and an
increasing need for cost-effective utilization of medical
resources, “ordering the right test for the right patient” will
be the major challenge for cardiac imaging in the future. To
achieve this ambitious goal, scientific knowledge must be
generated through interaction of prospective clinical trials,
guidelines, and registries (Fig. 1). As only registries finally
reflect every day imaging reality, they play an essential role
in this process. The EuroCMR registry offers the unique
platform for promoting quality and impact of CMR
imaging. As the number of participating centers and patient
enrollment is constantly growing, the authors are rather
Curr Cardiovasc Imaging Rep (2010) 3:171–174 173optimistic to pursue these objectives on an international
level.
Importantly, the EuroCMR registry is open to new
specific protocols. Scientists in the field of CMR are
encouraged to submit proposals about additional specific
protocols to the steering committee. Further details,
publications, and the current status of the registry are
accessible at www.eurocmr-registry.com.
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